Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen

详细信息    查看全文

• 作者：Ines Paule (1) (2)
  Hind Sassi (3)
  Anoosha Habibi (4)
  Kim PD Pham (3)
  Dora Bachir (4)
  Frédéric Galactéros (4)
  Pascal Girard (1) (2)
  Anne Hulin (3)
  Michel Tod (1) (2) (5)
  
• 刊名：Orphanet Journal of Rare Diseases
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：6
• 期：1
• 全文大小：692KB
• 参考文献：1. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW: Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. / N Engl J Med 1990,322(15):1037-045. CrossRef
  2. Cokic VP, Smith RD, Beleskin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, Schechter AN: Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependant activation of soluble fetal hemoglobin by the nitric oxide-dependant activation of soluble guanylyl cyclase. / J Clin Invest 2003,111(2):231-39.
  3. Okpala IE: New therapies for sickle cell disease. / Hematol Oncol Clin North Am 2005,19(5):975-87. CrossRef
  4. Bartolucci P, Chaar V, Picot J, Bachir D, Habibi A, Fauroux C, Galactéros F, Colin Y, Le Van Kim C, El Nemer W: Decreased sickle red blood cell adhesion to laminin by hudroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. / Blood 2010,116(12):2152-159. CrossRef
  5. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR, the investigators of the multicenter study of hydroxyurea in sickle cell anemia: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. / N Engl J Med 1995, 332:1317-322. CrossRef
  6. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. / JAMA 2003, 289:1645-651. CrossRef
  7. Platt OS: Hydroxyurea for the treatment of sickle cell anemia. / N Engl J Med 2008,358(13):1362-369. CrossRef
  8. Collins FS, Green ED, Guttmacher AE, Guyer MS: A vision for the future of genomics research. / Nature 2003,422(6934):835-47. CrossRef
  9. Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, Steinberg MH: Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. / Pharmacogenomics J 2007, 7:386-94. CrossRef
  10. Kumkhaek C, Kumkhaek C, Taylor JG, Zhu J, Hoppe C, Kato GJ, Rodgers GP: Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. / Br J Haematol 2008, 141:254-59. CrossRef
  11. Bachir D, Hulin A, Huet E, Habibi A, Nzouakou R, El Mahrab M, Astier A, Galacteros F: Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. / Hemoglobin 2007,31(4):417-25. CrossRef
  12. De Montalembert M, Bachir D, Hulin A, Gimeno L, Mogenet A, Bresson JL, Macquin-Mavier I, Roudot-Thoraval F, Astier A, Galactéros F: Pharmacokinetics of hydroxyurea 1000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. / Haematologica 2006,91(12):1685-688.
  13. Beal S, Sheiner LB, Boeckmann A, Bauer RJ: / NONMEM User's Guides (1989-009). Ellicott City, Icon Development Solutions; 2009.
  14. Brendel K, Comets E, Laffont C, Laveille C, Mentré F: Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. / Pharm Res 2006, 23:2036-049. CrossRef
  15. Beal SL: Ways to fit a PK model with some data below the quantification limit. / J Pharmacokinet Pharmacodyn 2001,28(5):481-04. CrossRef
  16. Cockcroft D, Gault MD: Prediction of creatinine clearance from serum creatinine. / Nephron 1976,16(1):31-1. CrossRef
  17. Krzyzanski W, Jusko WJ: Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. / J Pharmacokinet Biopharm 1998,26(4):385-08. CrossRef
  18. Lacroix BD, Friberg LE, Karlsson MO: Evaluating the IPPSE method for PKPD analysis [abstract]. [http://www.page-meeting.org/default.asp?abstract=1843] / Population Approach Group in Europe: 8-1 June 2010; Berlin Abstract Nr. 1843
  19. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO: Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. / AAPS J Published online 08-2-011.
  20. Gwilt PR, Tracewell WG: Pharmacokinetics and pharmacodynamics of hydroxyurea. / Clin Pharmacokinet 1998,34(5):347-58. CrossRef
  21. West GB, Brown JH, Enquist BJ: A general model for the origin of allometric scaling laws in biology. / Science 1997,276(5309):122-. CrossRef
  22. Green B, Duffull SB: What is the best size descriptor to use for pharmacokinetic studies in the obese? / Br J Clin Pharmacol 2004,58(2):119-3. CrossRef
  23. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB: Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. / Ann Intern Med 2008,148(12):939-55.
  24. Tang DC, Zhu J, Liu W, Chin K, Sun J, Chen L, Hanover JA, Rodgers GP: The hydroxyurea-induced small GTP-binding protein SAR modulates gamma-globin gene expression in human erythroid cells. / Blood 2005, 106:3256-263. CrossRef
  25. Darghouth D, Koehl B, Madalinski G, Heilier JF, Bovee P, Xu Y, Olivier MF, Bartolucci P, Benkerrou M, Pissard S, Colin Y, Galacteros F, Bosman G, Junot C, Roméo PH: Physiopathology of sickle cell disease is mirrored by red blood cells metabolome. / Blood 2010. prepublished online December 6
  26. Yasin Z, Witting S, Palascak MB, Joiner CH, Rucknagel DL, Franco RS: Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F. / Blood 2003,102(1):365-70. CrossRef
  
• 作者单位：Ines Paule (1) (2)
  Hind Sassi (3)
  Anoosha Habibi (4)
  Kim PD Pham (3)
  Dora Bachir (4)
  Frédéric Galactéros (4)
  Pascal Girard (1) (2)
  Anne Hulin (3)
  Michel Tod (1) (2) (5)
  
  1. Université de Lyon, Lyon, France
  2. EMR3738 CTO, Faculté de Médecine Lyon-Sud, Université Lyon 1, Oullins, France
  3. Laboratoire de Pharmacologie, AP-HP, GH H. Mondor, Université Paris Est-Créteil, Créteil, France
  4. Centre de référence pour les syndromes drépanocytaires majeurs, AP-HP, GH H. Mondor, Université Paris Est-Créteil, Créteil, France
  5. H?pital Croix-Rousse, Hospices Civils de Lyon, Lyon, France
  

文摘

Background Hydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the exposure-efficacy relationships and their variability, compare two dosing regimens by simulations and develop some recommendations for monitoring the treatment. Methods The models were built using population modelling software NONMEM VII based on data from two clinical studies of SCA adult patients receiving 500-2000 mg of HU once daily. Fetal hemoglobin percentage (HbF%) and mean corpuscular volume (MCV) were used as biomarkers for response. A sequential modelling approach was applied. Models were evaluated using simulation-based techniques. Comparisons of two dosing regimens were performed by simulating 10000 patients in each arm during 12 months. Results The PK profiles were described by a bicompartmental model. The median (and interindividual coefficient of variation (CV)) of clearance was 11.6 L/h (30%), the central volume was 45.3 L (35%). PK steady-state was reached in about 35 days. For a given dosing regimen, HU exposure varied approximately fivefold among patients. The dynamics of HbF% and MCV were described by turnover models with inhibition of elimination of response. In the studied range of drug exposures, the effect of HU on HbF% was at its maximum (median Imax was 0.57, CV was 27%); the effect on MCV was close to its maximum, with median value of 0.14 and CV of 49%. Simulations showed that 95% of the steady-state levels of HbF% and MCV need 26 months and 3 months to be reached, respectively. The CV of the steady-state value of HbF% was about 7 times larger than that of MCV. Simulations with two different dosing regimens showed that continuous dosing led to a stronger HbF% increase in some patients. Conclusions The high variability of response to HU was related in part to pharmacokinetics and to pharmacodynamics. The steady-state value of MCV at month 3 is not predictive of the HbF% value at month 26. Hence, HbF% level may be a better biomarker for monitoring HU treatment. Continuous dosing might be more advantageous in terms of HbF% for patients who have a strong response to HU. Trial Registration The clinical studies whose data are analysed and reported in this work were not required to be registered in France at their time. Both studies were approved by local ethics committees (of Mondor Hospital and of Kremlin-Bicetre Hospital) and written informed consent was obtained from each patient.